Latest News and Press Releases

BOSTON, June 22, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision...

BOSTON, June 09, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (“Tango”) (Nasdaq: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of...

BOSTON, June 08, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (“Tango”) (Nasdaq: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of...

Initial data from ongoing Phase 1/2 trial in patients with second and third line PDAC treated with vopimetostat and daraxonrasib showed 6-month PFS rate of 90% (median PFS not yet reached) suggesting...

BOSTON, June 05, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that, effective June 1, 2026, the Compensation Committee of Tango Therapeutics' Board of Directors...

First clinical data from PRMT5/RAS(ON) combination trial to be presented in 2026 Cash position of $380 million as of March 31, 2026, with runway into 2028 beyond anticipated key data inflection...

BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that effective May 1, 2026, the Compensation Committee of Tango Therapeutics' Board of Directors...

-  Matthew Gall appointed Chief Financial Officer  --  Additional key appointments add expertise in clinical operations, corporate strategy and project leadership  - BOSTON, April 15, 2026 (GLOBE...

BOSTON, March 06, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that, effective February 2, 2026, the Compensation Committee of Tango Therapeutics' Board of...

Initial Phase 1/2 trial data of vopimetostat in combination with Revolution Medicines’ RAS(ON) inhibitors in MTAP-deleted pancreatic cancer in 2026 with continued robust patient enrollment New...